Omeros (NASDAQ:OMER) Shares Gap Down – What’s Next?

Omeros Co. (NASDAQ:OMER)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $10.11, but opened at $9.90. Omeros shares last traded at $10.21, with a volume of 91,339 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. D. Boral Capital began coverage on shares of Omeros in a research report on Monday. They set a “buy” rating and a $36.00 price objective on the stock. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 target price for the company. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Trading Down 1.1 %

The business has a 50-day moving average price of $7.33 and a 200 day moving average price of $5.28. The stock has a market capitalization of $579.50 million, a P/E ratio of -4.33 and a beta of 1.96.

Hedge Funds Weigh In On Omeros

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC raised its position in shares of Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares in the last quarter. Geode Capital Management LLC raised its position in Omeros by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after purchasing an additional 6,839 shares during the period. MML Investors Services LLC lifted its stake in shares of Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Omeros by 15.9% in the 3rd quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 8,010 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Omeros in the 3rd quarter worth approximately $305,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.